Results 231 to 240 of about 98,417 (285)

CAR-T cells directed toward PD-L1 demonstrate potent, antigen-specific activity against cholangiocarcinoma: A proof of concept study. [PDF]

Mol Ther Oncol
Gondaliya P, Luo Y, Sayyed AA, Zinn DA, Qie Y, Yan IK, Driscoll J, Patel PB, Li S, Qin H, Patel T.   +10 more
europepmc   +1 more source

Clinicopathological Features, Treatment Patterns, and Long‐Term Survival in Patients With Testicular Cancer: A Retrospective Cohort Study

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Testicular cancer represents the most common solid tumor in young adult males and is associated with excellent long‐term survival outcomes. Aim The aim of this study is to evaluate clinical and pathological characteristics, treatment strategies, and survival outcomes of a large Romanian institutional cohort.
Emanuiela Florentina Rohozneanu, Ciprian Deac, Călin Ioan Căinap   +2 more
wiley   +1 more source

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial. [PDF]

ESMO Open
Bedke J, van der Heijden MS, Sonpavde G, Galsky MD, Liao W, Shi L, Blum SI, Mitra S, Patel MY, Powles T.   +9 more
europepmc   +1 more source

Change in skeletal muscle mass during systemic cancer treatment: a systematic review and meta-analysis. [PDF]

Acta Oncol
Svendsen L, Jensen S, Hansen S, Sørensen V, Johansen C, Suetta C, Pappot H, Simonsen C, Hermann Tang L, Oksbjerg Dalton S, Ammitzbøll G, Skjødt Rafn B.   +11 more
europepmc   +1 more source

Epigenetic evolution of bladder cancer from cellular origin to clinical translation

Clinical and Translational Discovery, Volume 6, Issue 3, June 2026.
EpiTrace‐based lineage inference supports a proposed model in which TM4SF1‐positive plastic cancer subpopulations contribute to intratumoural heterogeneity and therapy resistance in bladder cancer. This framework links epigenetic tumour evolution to urine tumour DNA methylation‐based detection and conditionally reprogrammed cell‐based ex vivo drug ...
Kaiyu Qian, Zilin Xu, Zhizhuang Chen, Mengxue Yu, Hongwei Peng, Fangjin Chen, Gang Wang, Yu Xiao, Lingao Ju   +8 more
wiley   +1 more source

Gemcitabine-Induced Lung Injury Masquerading as ARDS in a Patient With Metastatic Renal Medullary Carcinoma: A Case Report. [PDF]

Cureus
Worku D, Gelaye A, Gezahegn S.
europepmc   +1 more source

Biliary Tract Carcinoma: Real-World Evidence in a Developing Country. [PDF]

Cureus
Lema M, Lema C, Preciado B, Hoyos Duque S, Luján M, Aguirre D, Bonilla C, Gómez D, Pérez E, Pineda M, Patiño S.   +10 more
europepmc   +1 more source

Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study. [PDF]

BMC Cancer
Sobeih ME, Helal M, Yahia M, Khorshid O.
europepmc   +1 more source

When Carcinoma Meets Sarcoma: A Rare Case of Pancreatic Carcinosarcoma and Review of Literature. [PDF]

Clin Case Rep
Abedini P, Sanei B, Hajihashemi A, Sanei M, Firouzfar A.   +4 more
europepmc   +1 more source

Targeting cancer-associated fibroblast-activated HGF/c-MET pathway inhibits extrahepatic cholangiocarcinoma progression and restores gemcitabine therapeutic sensitivity. [PDF]

Acta Pharm Sin B
Bai M, Yue P, Fu W, Zhong R, Huang C, Jiang N, Gao L, Mi N, Ma H, Lu Y, Tian L, Zhao J, Zhang Z, Zhang Y, Zhang J, Ren Y, Yu H, Yao J, Li D, Lin Y, Meng W.   +20 more
europepmc   +1 more source